Laurent Hennequin

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes et al. · PubMed · 2002 · 802 citations

Medicine, Medicinal Chemistry, Pharmacology +15

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin et al. · Cancer Research · 2005 · 711 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>N</i>-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2<i>H</i>-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor

Laurent Hennequin, J M Allen, J. Breed et al. · Journal of Medicinal Chemistry · 2006 · 367 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas et al. · Journal of Medicinal Chemistry · 2002 · 308 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker et al. · Molecular Oncology · 2009 · 256 citations · Full text

Medicine, Oncology, Pharmacology +10